Virpax Advances Envelta™ Development with NCATS Under CRADA Agreement
Cannabis Law Report
NOVEMBER 10, 2021
–(BUSINESS WIRE)– #pharma — Virpax ® Pharmaceuticals, Inc. Once completed, it is our intention to immediately submit our IND package to the FDA so that we may begin human trials,” commented Virpax’s Chairman & CEO Anthony P. For more information, please visit www.virpaxpharma.com. Forward-Looking Statement.
Let's personalize your content